中国全科医学 ›› 2018, Vol. 21 ›› Issue (23): 2808-2813.DOI: 10.3969/j.issn.1007-9572.2017.00.236

• 专题研究 • 上一篇    下一篇

慢性阻塞性肺疾病患者合并周围神经病变情况及临床意义研究

刘贤兵*,李芳,陈晓萍   

  1. 324000浙江省衢州市人民医院呼吸内科
    *通信作者:刘贤兵,副主任医师;E-mail:dabinglxb@qq.com
  • 出版日期:2018-08-15 发布日期:2018-08-15
  • 基金资助:
    基金项目:浙江省衢州市科技局2015年指导性科技项目(2015065)

Clinical Characteristics and Significance of Peripheral Neuropathy in Patients with Chronic Obstructive Pulmonary Disease #br#

LIU Xian-bin*,LI Fang,CHEN Xiao-ping   

  1. Department of Respiratory Medicine,People's Hospital of Quzhou,Quzhou 324000,China
    *Corresponding author:LIU Xian-bin,Associate chief physician;E-mail:dabinglxb@qq.com
  • Published:2018-08-15 Online:2018-08-15

摘要: 目的 探讨慢性阻塞性肺疾病(COPD)患者合并周围神经病变的情况及营养神经干预治疗对患者预后的影响。方法 选取2015年6月—2016年6月衢州市人民医院就诊的COPD患者120例为研究对象,行肌电图检查,分为周围神经病变组(72例)及无周围神经病变组(48例)。周围神经病变组采用随机数字表法分为干预亚组36例和未干预亚组36例,干预亚组给予甲钴胺联合硫辛酸治疗3周。所有患者入组后随访12个月,每次随访时统计发病次数,完成肺功能检测、慢性阻塞性肺疾病评估测试(CAT)、改良英国医学研究学会呼吸困难指数(mMRC)、医院焦虑抑郁量表(HAD)。结果 周围神经病变组患者男性、吸烟率、年发病次数、CAT评分、mMRC级别、合并焦虑/抑郁比例较无周围神经病变组高,第1秒用力呼气末容积(FEV1)较无周围神经病变组低(P<0.05)。周围神经病变组有症状者年发病次数、CAT评分、mMRC级别、合并焦虑/抑郁比例、症状分级较无症状者高,FEV1较无症状者低(P<0.05)。COPD合并周围神经病变患者干预亚组与未干预亚组FEV1、CAT评分、mMRC级别、HAD评分治疗方法与时间存在交互作用(P<0.05),治疗方法及时间主效应显著(P<0.05)。干预前两组FEV1、CAT评分、mMRC级别、HAD评分比较,差异均无统计学意义(P>0.05);随访第1、3、6、9、12个月干预亚组FEV1较未干预亚组高,CAT评分、mMRC级别、HAD评分较未干预亚组低(P<0.05)。干预亚组与未干预亚组不同时间点合并焦虑/抑郁比例比较,差异有统计学意义(P<0.05),其中干预前、随访第1个月两组合并焦虑/抑郁比例比较,差异无统计学意义(P>0.05);随访第3、6、9、12个月干预亚组合并焦虑/抑郁比例低于未干预亚组(P<0.05);干预亚组随访第6个月合并焦虑/抑郁比例低于干预前和随访第1、3个月,随访第9、12个月合并焦虑/抑郁比例高于随访第6个月(P<0.003)。结论 周围神经病变是COPD常见的合并症,与性别、吸烟、病情相关,对患者的生活质量及预后均有影响;大部分患者早期并无症状,出现症状者多病情较重;营养神经干预治疗可改善患者生活质量及预后。

关键词: 肺疾病, 慢性阻塞性;周围神经系统疾病;生活质量;焦虑;抑郁;预后

Abstract: Objective To investigate the clinical characteristics of peripheral neuropathy in patients with chronic obstructive pulmonary disease(COPD) and the effect of nutritional nerve intervention on patient prognosis.Methods The study included 120 patients who were diagnosed with COPD and treated in the People's Hospital of Quzhou between June 2015 and June 2016.All patients were examined for myoelectric activity.Patients were divided into a peripheral neuropathy group(n=72) and a non-peripheral neuropathy group(n=48) based on myoelectric activity.The peripheral neuropathy group was further divided into an intervention subgroup(n=36) and a non-intervention subgroup(n=36) using the random number table method.Patients in the intervention subgroup were treated with mecobalamin combined with alpha lipoic acid for 3 weeks.All patients were followed up for 12 months after group assignment.In each follow-up visit,the number of episodes of exacerbation was recorded and the patients received a pulmonary function test,a COPD assessment test(CAT),and evaluation according to the modified British Medical Research Council Dyspnea Scale(mMRC) and Hospital Anxiety and Depression Scale(HAD).Data were collected and analyzed.Results The proportion of men or smokers was significantly higher in the peripheral neuropathy group than in the non-peripheral neuropathy group(P<0.05).The number of annual exacerbation episodes,CAT score,mMRC grade,and patients with anxiety/depression also increased significantly in the peripheral neuropathy group(P<0.05).FEV1 was lower in the peripheral neuropathy group than in the non-peripheral neuropathy group(P<0.05).The number of annual exacerbation episodes,CAT score,mMRC grade,the proportion of the patients with anxiety/depression,and the grading of symptoms were significantly higher in symptomatic patients with peripheral neuropathy than in those without symptoms,and FEV1 decreased in symptomatic patients(P<0.05).There were interactive effects between FEV1,CAT score,mMRC grade,HAD score and treatment,and time in both the intervention subgroup and non-intervention subgroup(P<0.05).The main effects of treatment and time were significant(P<0.05).There were no significant differences in baseline FEV1,CAT score,mMRC grade,and HAD score between the intervention subgroup and non-intervention subgroup(P>0.05).At 1,3,6,9,and 12 months of follow up,FEV1 significantly increased,and CAT score,mMRC grade,and HAD score significantly decreased in the intervention subgroup compared with the non-intervention subgroup(P<0.05);The proportion of patients with anxiety/depression in the two subgroups at different time points was also significantly different(P<0.05).The proportion of anxiety/depression patients in the two subgroups did not differ significantly before intervention and at 1 month of follow up(P>0.05);however,at 3,6,9,and 12 months,the proportion was significantly lower in the intervention subgroup than in the non-intervention subgroup(P<0.05).In the intervention subgroup,the proportion of patients with anxiety/depression at 6 months was lower than that before intervention as well as at 1 and 3 months,and the proportions at 9 and 12 months were higher than that at 6 months(P<0.003).Conclusion Peripheral neuropathy is a common complication of COPD,and is associated with gender,smoking and severity of COPD.The condition significantly affects quality of life and patient prognosis.Most patients are asymptomatic in the early stage,and symptomatic patients often have a severe condition.Neuro-nutrient therapy can improve both prognosis and the quality of life of patients.

Key words: Pulmonary disease, chronic obstructive;Peripheral nervous system diseases;Quality of life;Anxiety;Depression;Prognosis